- Bowenoid papulosis treatments, including topical agents, cryotherapy, laser ablation, and antiviral medications, are critical in managing this HPV-associated condition, with growing relevance in dermatology and sexually transmitted infection (STI) care due to their effectiveness, minimal invasiveness, and ability to prevent malignant progression in high-risk patients
- The rising demand for Bowenoid papulosis treatment is largely driven by increasing global STI incidence, enhanced awareness regarding HPV-related skin conditions, and a growing inclination toward early intervention and preventive care
- North America dominated the Bowenoid papulosis treatment market with the largest revenue share of 39.5% in 2024, attributed to widespread public health initiatives, well-established healthcare infrastructure, and proactive screening programs, especially in the U.S. where early detection and specialized dermatological services are more accessible
- Asia-Pacific is expected to be the fastest growing region in the Bowenoid papulosis treatment market during the forecast period, owing to improved healthcare access, increasing awareness of STIs, and expanding public health education
- The topical segment dominated the Bowenoid papulosis treatment market with a market share of 42.5% in 2024, supported by its non-invasive nature, ease of self-application, and cost-effectiveness, particularly in outpatient and home-care settings
